Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman \> 16 and \< 60 years old with HI less 24 hours in progression and Glasgow between \< 13~* Acceptance of family to participate (first grade)~Exclusion Criteria:~* Previous head injury with severe disability~* History of neurological or psychiatric disease with severe disability~* Administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone~* Very poor possibilities for survival~* Use of Administration of THAM, mannitol, barbiturates, corticosteroids, scavengers of free radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist, antagonists of neurotransmitters before randomization~* isolated lesions in brain stem~* Allergy to the drug~* Hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease~* Management previous in other Hospital~* Pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): 20 mg oral during 10 days
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).